Viread · DIN 02247128 · 300 mg · tablet
Limited Use, Reason for Use code 517, 518, 519, 520, 521, 522 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 517, 518, 519, 520, 521, 522 required
Write on scriptone applicable Reason for Use code, 517 or 518 or 519 or 520 or 521 or 522 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 517, 518, 519, 520, 521, 522
Reason for Use code 517
Confirmed chronic Hepatitis B infection in persons with
- HBV DNA greater than or equal to 1000 IU/mL
AND
- ALT levels greater than ULN
OR
- Evidence of fibrosis
OR
- Documented evidence of cirrhosis
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 518
For patients with chronic Hepatitis B infection who have a contraindication, intolerance or inadequate response to one or more of the following: lamivudine, entecavir, adefovir or telbivudine.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 519
Patient is pregnant (2nd trimester or later) with HBV DNA greater than 1,000,000 IU/mL.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 520
Patients with chronic Hepatitis B infection currently receiving treatment with tenofovir and requires treatment continuation.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 521
Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 522
For HIV/AIDS.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Viread · DIN 02247128
Manufacturer: Gilead Sciences Canada, Inc.; listing date 2007-01-02
Health Canada: Marketed since 2009-05-21 · brand VIREAD · ATC J05AF07 TENOFOVIR DISOPROXIL · form Tablet · route Oral · ingredients TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Gilead sciences canada inc · schedule Prescription
Ministry pays: $4.8884 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247128)
Source record
DIN 02247128: Viread
Raw flags: sec12=Y, sec3=Y
Item: 081800083; group id 113; item number 0195; lccId 00297; manufacturer id GIL
Source form: Tab; strength: 300mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $19.5537; ministry $4.8884
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247128
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71368
Interchangeable products
Apo-Tenofovir · DIN 02451980 · $4.8884
Auro-Tenofovir · DIN 02460173 · $4.8884
Jamp-Tenofovir · DIN 02479087 · $4.8884
Mint-Tenofovir · DIN 02512939 · $4.8884
Mylan-Tenofovir Disoproxil · DIN 02452634 · $4.8884
Nat-Tenofovir · DIN 02472511 · $4.8884
PMS-Tenofovir · DIN 02453940 · $4.8884
Tenofovir · DIN 02512327 · $4.8884
Tenofovir · DIN 02523922 · $4.8884
Teva-Tenofovir · DIN 02403889 · $4.8884
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247128
Shortage record checked October 6, 2026